Cyclosporine Ophthalmic — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Dry Eye (Keratoconjunctivitis sicca)

• Artificial tears (carboxymethylcellulose
• Artificial tears (carboxymethylcellulose 0.5%)

Other medications in Ophthalmology

• Dorzolamide
• Faricimab
• Fluorescein
• Latanoprost
• Latanoprostene Bunod
• Lifitegrast
• Methazolamide
• Netarsudil

About Cyclosporine Ophthalmic

Struggling with chronic dry, irritated eyes? Cyclosporine ophthalmic eye drops offer a powerful solution, targeting the root cause of discomfort rather than just masking symptoms. Chronic dry eye, medically known as keratoconjunctivitis sicca, is more than just an occasional nuisance. It's a persistent condition characterized by insufficient tear production or poor tear quality, leading to symptoms like burning, stinging, grittiness, redness, and even blurred vision. These discomforts can significantly impact daily activities, from reading to driving. This is where cyclosporine ophthalmic eye drops come into play. What Cyclosporine Ophthalmic Treats

Cyclosporine ophthalmic is specifically approved to increase natural tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with chronic dry eye. Unlike artificial tears, which offer temporary lubrication, cyclosporine addresses the underlying inflammatory process that often contributes to dry eye disease, providing more lasting relief. How It Works

At its core, cyclosporine is an immunomodulator. In the context of dry eye, it works by suppressing the immune response that causes inflammation in the lacrimal glands – the glands responsible for producing tears. By reducing this inflammation, cyclosporine helps to restore the normal function of these glands, allowing your eyes to produce their own natural tears more effectively. This process isn't instant; it typically takes several weeks to notice significant improvement, as the medication needs time to reduce inflammation and allow the tear glands to recover. The Cost of Relief

While highly effective, prescription eye drops like cyclosporine ophthalmic can be quite expensive. Without adequate insurance coverage, a single monthly supply can cost hundreds of dollars, making consistent, long-term treatment a financial burden for many. This high cost often forces individuals to choose between their eye health and other essential expenses. TheDrugClub: Your Solution for Affordable Access

At TheDrugClub, we believe that managing chronic conditions like dry eye shouldn't break the bank. That's why we're committed to making essential medications, including cyclosporine ophthalmic, accessible and affordable for our members. But the benefits don't stop there. We also offer free home delivery, ensuring your medication arrives conveniently at your doorstep. Imagine receiving your essential dry

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Cyclosporine Ophthalmic is approved for (FDA label)

CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). ( 1 ) CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye) ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: June 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Cyclosporine Ophthalmic (FDA label)

Ophthalmic solution containing cyclosporine 0.9 mg/mL ( 3 ) Ophthalmic solution containing cyclosporine 0.9 mg/mL ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: 48c3d8a3-4289-4b52-9189-58b48596095c. SPL document ID: 0c4be5cb-4e73-413f-847c-66babed20757. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Cyclosporine Ophthalmic (FDA label)

The most common adverse reactions following the use of CEQUA (cyclosporine ophthalmic solution) 0.09% was instillation site pain (22%) and conjunctival hyperemia (6%) ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, 769 subjects received at least 1 dose of cyclosporine ophthalmic solution. The majority of the treated subjects were female (83%).

Source: FDA prescribing information (DailyMed). Set ID: 48c3d8a3-4289-4b52-9189-58b48596095c. SPL document ID: 0c4be5cb-4e73-413f-847c-66babed20757. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Cyclosporine Ophthalmic (FDA label)

None. ( 4 ) None ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: 48c3d8a3-4289-4b52-9189-58b48596095c. SPL document ID: 0c4be5cb-4e73-413f-847c-66babed20757. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Cyclosporine Ophthalmic (FDA label)

To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces ( 5.1 ). 5.1 Potential for Eye Injury and Contamination To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces. 5.2 Use with Contact Lenses CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.

Source: FDA prescribing information (DailyMed). Set ID: 48c3d8a3-4289-4b52-9189-58b48596095c. SPL document ID: 0c4be5cb-4e73-413f-847c-66babed20757. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.